The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 15 April 2024 at 15:30 under RNS No 6703K:
- A typographical correction to the share price for the transaction shown in the table below.
All other details to the original announcement remain unchanged.
The amended table is shown below.
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
|
a) |
Name |
David Redfern |
|||
|
b) |
Position/status |
Chief Strategy Officer |
|||
|
c) |
Initial notification/ amendment |
Amendment |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024, on Ordinary Shares held within an ISA |
|||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
£16.3860 |
19 |
||||
|
d) |
Aggregated information |
N/A (single transaction) |
|||
|
Aggregated volume Price |
|||||
|
e) |
Date of the transaction |
2024-04-12 |
|||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|||